Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice

Bioscience, Biotechnology and Biochemistry

Volumn 79, Issue 11, 2015, Pages 1838-1844

  Ohba, Takuya ^a   Yoshino, Yuta ^a   Ishisaka, Mitsue ^a   Abe, Naohito ^a   Tsuruma, Kazuhiro ^a   Shimazawa, Masamitsu ^a   Oyama, Masayoshi ^a   Tabira, Takeshi ^b,c   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c Kawamura Hospital   (Japan)

Author keywords

Acetylcholinesterase; Cognitive impairment; Huperzia serrata; Huperzine A; Scopolamine

Indexed keywords

BRAIN; NEURODEGENERATIVE DISEASES;

ACETYLCHOLINESTERASE; COGNITIVE IMPAIRMENT; HUPERZIA SERRATA; HUPERZINE A; SCOPOLAMINE;

MAMMALS;

ACETYLCHOLINESTERASE; ALKALOID; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HUPERZINE A; PLANT EXTRACT; SCOPOLAMINE BROMIDE; SESQUITERPENE;

ALZHEIMER DISEASE; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; CHEMISTRY; COGNITION DISORDERS; DRUG EFFECTS; HUPERZIA; JAPAN; MEMORY DISORDERS; MOUSE; PATHOLOGY;

ACETYLCHOLINESTERASE; ALKALOIDS; ALZHEIMER DISEASE; ANIMALS; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HUPERZIA; JAPAN; MEMORY DISORDERS; MICE; PLANT EXTRACTS; SCOPOLAMINE HYDROBROMIDE; SESQUITERPENES;

EID: 84946949622     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1080/09168451.2015.1052773     Document Type: Article

References (31)

1. Watson WJ, Seiden HS. Alzheimer's disease: a current review. Can. Fam. Physician. 1984;30:595-599.
2. Gomez-Ramirez J, Wu J. Network-based biomarkers in Alzheimer's disease: review and future directions. Front. Aging Neurosci. 2014;6:12.
3. Takashima A, Noguchi K, Sato K, et al. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl. Acad. Sci. USA. 1993;90:7789-7793.
4. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry. 1999;66:137-147.
5. Kar S, Slowikowski SP, Westaway D, et al. Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J. Psychiatry Neurosci. 2004;29:427-441.
6. Gil-Bea FJ, García-Alloza M, Domínguez J, et al. Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit. Neurosci. Lett. 2005;375:37-41.
7. Sugimoto H, Yamanish Y, Iimura Y, et al. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr. Med. Chem. 2000;7:303-339.
8. Lilienfeld S. Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002;8:159-176.
9. Anagnostaras SG, Maren S, Fanselow MS. Scopolamine selectively disrupts the acquisition of contextual fear conditioning in rats. Neurobiol. Learn. Mem. 1995;64:191-194.
10. 2 ameliorates scopolamine-induced learning deficit in mice. Biol. Pharm. Bull. 2009;32:1710-1715.
11. Uchida S, Endo S, Akita K, et al. The cyanine dye NK-4 improves scopolamine-induced memory impairments in mice. Biol. Pharm. Bull. 2012;35:1831-1835.
12. Guo B, Xu L, Wei Y, et al. [Research advances of Huperzia serrata (Thunb.) Trev]. Zhongguo Zhong Yao Za Zhi. 2009;34:2018-2023.
13. Zhang HY, Zheng CY, Yan H, et al. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chem. Biol. Interact. 2008;175:396-402.
14. Ma X, Tan C, Zhu D, et al. Huperzine A from Huperzia species-an ethnopharmacolgical review. J. Ethnopharmacol. 2007;113:15-34.
15. Suh WH, Suslick KS, Suh YH. Therapeutic agents for Alzheimer's disease. Curr. Med. Chem. 2005;5:259-269.
16. Tang XC, Han YF. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Rev. 1999;5:281-300.
17. Ye JW, Cai JX, Wang LM, et al. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J. Pharmacol. Exp. Ther. 1999;288:814-819.
18. Szypuła WJ, Kiss AK, Pietrosiuk A, et al. Determination of huperzine a in Huperzia selago plants from wild population and obtained in in vitro culture by high-performance liquid chromatography using a chaotropic mobile phase. Acta Chromatographica. 2011;23:339-352.
19. Ferreira A, Rodrigues M, Fortuna A, et al. Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology. Phytochem. Rev. 2014. DOI 10.1007/s11101-014-9384-y.
20. Bai DL, Tang XC, He XC. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr. Med. Chem. 2000;7:355-374.
21. Kasa P, Papp H, Kasa P Jr, et al. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience. 2000;101:89-100.
22. Saxena A, Qian N, Kovach IM, et al. Identification of amino acid residues involved in the binding of huperzine A to cholinesterases. Protein Sci. 1994;3:1770-1778.
23. Mandillo S, Tucci V, Hölter SM, et al. Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a crosslaboratory study. Physiol. Genomics. 2008;34:243-255.
24. Kumar H, Kim BW, Song SY, et al. Cognitive enhancing effects of alpha asarone in amnesic mice by influencing cholinergic and antioxidant defense mechanisms. Biosci. Biotechnol. Biochem. 2012;76:1518-1522.
25. Oike Y, Hata A, Mamiya T, et al. Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum. Mol. Genet. 1999;8:387-396.
26. Zhu XD, Giacobini E. Second generation cholinesterase inhibitors: Effect of (L)-huperzine-A on cortical biogenic amines. J. Neurosci. Res. 1995;41:828-835.
27. Gordon RK, Nigam SV, Weitz JA, et al. The NMDA receptor ion channel: a site for binding of huperzine A. J. Appl. Toxicol. 2001;21:S47-S51.
28. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin. 2006;27:1-26.
29. Shannon HE, Peters SC. A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. J. Pharmacol. Exp. Ther. 1990;255:549-553.
30. Ukai M, Kobayashi T, Kameyama T. Characterization of the effects of scopolamine on the habituation of exploratory activity: differential effects of oxotremorine and physostigmine. Gen. Pharmacol. 1994;25:433-438.
31. Hornick A, Schwaiger S, Rollinger JM, et al. Extracts and constituents of Leontopodium alpinum enhance cholinergic transmission: Brain ACh increasing and memory improving properties. Biochem. Pharmacol. 2008;76:236-248.